Lattice Medical
Lattice Medical is a French regenerative-medicine company developing 3D-printed, bioresorbable implants — MATTISSE for post-mastectomy breast reconstruction and RODIN for subcutaneous tissue defects — serving hospitals and patients across Europe, the USA, and Brazil, with commercialization pending CE marking.
- Company typePrivate
- Founded2017
- HeadquartersLoos, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lattice Medical does
Lattice Medical SAS is a French regenerative-medicine company headquartered in Loos (Lille metropolitan area), founded in 2017 to commercialize tissue-engineering and 3D-printing research originating from Lille University Hospital and the University of Lille. The company designs, develops, and manufactures bioresorbable implantable medical devices for soft-tissue reconstruction, with two core products: MATTISSE, a 3D-printed breast bioprosthesis for autologous reconstruction following total mastectomy, and RODIN, a 3D-printed matrix for reconstruction of large subcutaneous tissue defects developed with the French Defence Innovation Agency under the HYPOFILL project. Manufacturing takes place at an ISO7 clean-room 3D printing farm installed in partnership with Cousin Surgery, using proprietary medical-grade lactic-acid biopolymer filaments, with related services commercialized through the wholly-owned Lattice Services subsidiary.
The business model is hardware sales of Class III implantable medical devices to hospitals and healthcare providers, distributed via direct B2B engagement with leading university hospitals and clinical investigation centers. Commercial revenue is gated on regulatory approval: MATTISSE is pursuing CE marking targeted for 2026 (with FDA preparation underway) following the multi-country TIDE clinical investigation; RODIN revenue is anticipated from 2027. Pricing is not publicly disclosed but operates on a quote-based B2B medical-device basis. The company is currently pre-commercial, with cumulative disclosed funding exceeding €60 million across seed, EIC Accelerator grant and equity, Series A, France 2030 grant, and a €43 million Series B in October 2025.
The company sells into a defined unmet need: breast cancer affects roughly 1 in 8 women, about 40% undergo mastectomy, and only ~20% currently receive reconstruction due to invasiveness, donor-site morbidity, and long-term risks of existing options. MATTISSE addresses this by enabling single-surgery reconstruction that regenerates vascularized adipose tissue within six months while the biopolymer progressively resorbs. Geographic footprint covers France, Spain, the USA, and Brazil, supported by a network of clinical sites (CHU Lille, CHRU Strasbourg, Hôpital Tenon AP-HP, Institut Gustave Roussy, Clinique de l'Atlantique) and institutional partners including BPI France, the European Innovation Council Fund, French Tech, Hauts-de-France Region, and Lille European Metropolis. The company employs approximately 25 people as of January 2024 and is expanding headcount under the LIPOTEC programme.
Lattice Medical firmographics
Firmographics- Name
- Lattice Medical
- Legal name
- LATTICE MEDICAL SAS
- Website
- https://lattice-medical.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lattice Medical is a French regenerative-medicine company developing 3D-printed, bioresorbable implants — MATTISSE for post-mastectomy breast reconstruction and RODIN for subcutaneous tissue defects — serving hospitals and patients across Europe, the USA, and Brazil, with commercialization pending CE marking.
- Ownership category
- akta.pro rank
Lattice Medical industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
- akta.pro secondary industries
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
Keywords
Where Lattice Medical is headquartered
LocationHeadquarters
- HQ city
- Loos
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Lattice Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Medical Device Sales (MATTISSE): Sale of implantable medical devices for breast reconstruction and tissue regeneration. The company manufactures custom 3D-printed bioprosthetic implants for patients requiring reconstruction after mastectomy. Revenue will be generated upon CE marking approval and commercial launch in Europe (targeted 2026).
- Medical Device Sales (RODIN): Sale of implantable tissue matrices for hypodermal reconstruction. Target market includes both civilian and defense applications. Revenue anticipated from 2027 in Europe.
- Lattice Services: Services division offering medical-grade 3D printing capabilities and expertise, including filaments and manufacturing services for implantable medical devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Not publicly disclosed - medical device pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Lattice Medical product offering
Product offeringCore offering
Lattice Medical designs and manufactures 3D-printed, bioresorbable medical devices for reconstructive surgery. Its lead product, MATTISSE, is a resorbable breast bioprosthesis intended for post-mastectomy breast reconstruction in a single surgical procedure, while RODIN is a 3D-printed matrix for subcutaneous tissue reconstruction. The company also operates Lattice Services, supplying medical-grade 3D printing filaments and contract additive-manufacturing services.
Product overview
Lattice Medical is a regenerative medicine company specializing in tissue engineering, biomaterials, and 3D printing for reconstructive surgery. The company's portfolio consists of two main medical devices: MATTISSE, a 3D-printed resorbable breast bioprosthesis for post-mastectomy reconstruction, and RODIN, a 3D-printed tissue matrix for subcutaneous tissue reconstruction. Additionally, Lattice Services provides medical-grade 3D printing filaments and manufacturing capabilities. The company operates a proprietary production facility with 3D printing technology in an ISO7 clean room environment.
Differentiator
Problem solved
Functional benefit
Brands
- MATTISSE: 3D-printed resorbable breast bioprosthesis for post-mastectomy breast reconstruction using tissue engineering technology
- RODIN
- Lattice Services
Products and services
- MATTISSE MATTISSE is a 3D-printed, bioresorbable breast bioprosthesis designed for post-mastectomy breast reconstruction in a single surgical procedure. It is intended for reconstructive surgeons and oncology centers treating breast cancer patients, enabling natural tissue regeneration via the patient's own adipose tissue.
- RODIN RODIN is a 3D-printed bioresorbable matrix indicated for subcutaneous tissue reconstruction, used by surgeons in reconstructive procedures where soft tissue support and regeneration are required.
- Lattice Services Lattice Services supplies medical-grade bioresorbable 3D printing filaments and provides contract additive-manufacturing services for medical device firms, supporting industrial customers developing biocompatible 3D-printed products.
Quantifiable outcome
- Regeneration of vascularized adipose tissue within 6 months post-implantation
- +3 more outcomes
Companies that use Lattice Medical
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Lattice Medical technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Lattice Medical partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- ONCOLille / INSERM CANTHER U1277coreResearch partnership for the LIPOTEC project focused on MATTISSE bioprosthesis reimbursement and understanding cancer treatment resistance mechanisms. Laboratory specializes in heterogeneity, plasticity, and resistance to cancer therapies.
- RougeGorge LingeriecoreCollaboration to develop the first evolutionary bra designed for post-reconstruction surgery support. One year of development resulted in a product specifically designed to accompany the evolution of breast reconstruction with the MATTISSE implant, incorporating adapted support, aesthetics, and healing considerations.
- Medicen Paris RegionminorParticipation in Chirurgie du Futur (Surgery of the Future) event organized by Medicen. Collaboration through cluster network for medical technology innovation and development.
- Cousin Biotech (now Cousin Surgery)corePartnership agreement for manufacturing of MATTISSE implants using 3D printing. Lattice Medical installed an innovative production unit in Cousin's ISO7 clean room, consisting of 3D printers for manufacturing implantable medical devices. This '3D printing farm' is dedicated to development and manufacturing of implantable medical devices and enables Lattice Medical to design applications beyond MATTISSE prosthesis in tissue engineering.
- FemTech FranceminorAssociation membership supporting creation and deployment of innovative projects dedicated to women's health. Highlights importance of developing specific innovations for breast reconstruction needs.
- Réseau EntreprendreminorBusiness support network providing mentorship and support for entrepreneurs.
- French Defence Innovation AgencycoreCollaboration under RAPID (Régime d'Appui à l'Innovation Dual) programme for HYPOFILL project developing RODIN implantable medical device for reconstruction of deep skin lesions.
- Hauts-de-France RegionminorRegional government support for innovation and entrepreneurship, supporting company presence at VivaTech 2026.
- Lille European Metropolis (MEL)minorMetropolitan authority supporting innovation ecosystem, with representation at VivaTech 2026.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Lattice Medical competitors and assessment
Company assessmentDirect peers
- BellaSeno: BellaSeno develops 3D-printed resorbable scaffolds for breast reconstruction and other tissue regeneration. Direct peer given its closely aligned approach of using additive manufacturing of bioresorbable implants to enable natural tissue regeneration, targeting similar patient populations and clinical use cases.
- CollPlant Biotechnologies: CollPlant is a regenerative medicine company developing bio-printed tissues and implants using its proprietary recombinant human collagen. Comparable due to its use of bioinks/biomaterials for 3D-printed soft tissue regeneration and its overlap with breast reconstruction and dermal applications.
- Establishment Labs: Establishment Labs (Motiva implants) is a global breast aesthetics and reconstruction company that has disrupted the breast implant market with innovative silicone implants. Peer in the same primary indication (breast reconstruction/augmentation) pursuing technology-led differentiation against incumbent players.
- Sientra: Sientra is a US-based breast aesthetics and reconstruction company selling breast implants exclusively to board-certified plastic surgeons. Direct peer in the breast implant/reconstruction market competing for the same plastic surgeon customer base.
- Polytech Health & Aesthetics: Polytech Health & Aesthetics is a European manufacturer of breast implants focused on quality, safety, and innovation in aesthetic and reconstructive surgery. Direct peer headquartered in Germany with overlapping European distribution and surgeon customer base.
- GC Aesthetics: GC Aesthetics is a global medical technology company providing silicone breast implants and related products for aesthetic and reconstructive surgery. Direct peer with global commercial reach and overlapping surgeon customer base across Europe, LATAM, and other geographies.
Emerging players
- Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic applications. Comparable through its pioneering use of 3D bioprinting for regenerative medicine, though focused more on liver and other tissues rather than breast reconstruction.
- Tepha Inc. Tepha develops bioresorbable polymers (P4HB) for use in medical implants and tissue engineering. Comparable as an enabling technology provider in the bioresorbable medical device space, relevant given Lattice Medical's reliance on proprietary biopolymer filaments.
Broad incumbents
- Mentor Worldwide (Johnson & Johnson): Mentor, a Johnson & Johnson MedTech company, is one of the world's largest manufacturers of breast implants for augmentation and reconstruction. Incumbent peer serving the same end market with extensive surgeon relationships, regulatory footprint, and reimbursement infrastructure.
- Allergan Aesthetics (AbbVie): Allergan Aesthetics, an AbbVie company, markets the NATRELLE line of breast implants and is a leading global incumbent in the breast reconstruction and aesthetics market. Broad incumbent competing directly in the same clinical setting with established regulatory and commercial presence.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Lattice Medical social profiles
Digital presenceLattice Medical compliance and trust
Trust signalCompliance1 record
Lattice Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lattice Medical leadership team
Management profileNumber of profiles
Profiles5 records
Lattice Medical subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lattice Medical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lattice Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lattice Medical
What does Lattice Medical do?
Lattice Medical designs and manufactures 3D-printed, bioresorbable medical devices for reconstructive surgery. Its lead product, MATTISSE, is a resorbable breast bioprosthesis intended for post-mastectomy breast reconstruction in a single surgical procedure, while RODIN is a 3D-printed matrix for subcutaneous tissue reconstruction. The company also operates Lattice Services, supplying medical-grade 3D printing filaments and contract additive-manufacturing services.
Is Lattice Medical a public or private company?
Lattice Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lattice Medical founded?
Lattice Medical was founded in 2017. It employs 11 to 50 people.
Where is Lattice Medical based?
Lattice Medical is headquartered in Loos, France, in the Europe region.
How does Lattice Medical make money?
Three revenue lines are on record. Medical Device Sales (MATTISSE) is the primary driver. The others are medical Device Sales (RODIN) and lattice Services.
Who are Lattice Medical's main competitors?
Direct peers on record are BellaSeno, CollPlant Biotechnologies, Establishment Labs, Sientra, Polytech Health & Aesthetics and GC Aesthetics. Emerging players are Organovo and Tepha Inc.. Broad incumbents are Mentor Worldwide (Johnson & Johnson) and Allergan Aesthetics (AbbVie).
Does Lattice Medical have an API?
No public API is recorded for Lattice Medical.
What industry is Lattice Medical in?
Lattice Medical's product category is Medical Devices. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339112 and its SIC code is 3841.